ECSP12012180A - Composición que comprende el péptido amiloide beta 1-6 acoplado a una partícula similar a virus y un auxiliar - Google Patents

Composición que comprende el péptido amiloide beta 1-6 acoplado a una partícula similar a virus y un auxiliar

Info

Publication number
ECSP12012180A
ECSP12012180A ECSP12012180A ECSP12012180A EC SP12012180 A ECSP12012180 A EC SP12012180A EC SP12012180 A ECSP12012180 A EC SP12012180A EC SP12012180 A ECSP12012180 A EC SP12012180A
Authority
EC
Ecuador
Prior art keywords
peptide
auxiliary
coupled
amiloid
beta
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Ana Graf
Peter Ulrich
Katja Baer
Georges Imbert
Marie Jose Hoellinger
Marie Emmanuelle Riviere
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012180(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP12012180A publication Critical patent/ECSP12012180A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ECSP12012180 2010-03-29 2012-09-25 Composición que comprende el péptido amiloide beta 1-6 acoplado a una partícula similar a virus y un auxiliar ECSP12012180A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10158273 2010-03-29
US36169710P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
ECSP12012180A true ECSP12012180A (es) 2012-10-30

Family

ID=42285305

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012180 ECSP12012180A (es) 2010-03-29 2012-09-25 Composición que comprende el péptido amiloide beta 1-6 acoplado a una partícula similar a virus y un auxiliar

Country Status (24)

Country Link
US (4) US20130011431A1 (enExample)
EP (1) EP2552489A1 (enExample)
JP (2) JP6088422B2 (enExample)
KR (1) KR20130018407A (enExample)
CN (2) CN104436212A (enExample)
AR (1) AR080810A1 (enExample)
AU (1) AU2011234656B2 (enExample)
BR (1) BR112012024708A2 (enExample)
CA (1) CA2793580A1 (enExample)
CL (1) CL2012002685A1 (enExample)
CO (1) CO6630127A2 (enExample)
EC (1) ECSP12012180A (enExample)
GT (1) GT201200265A (enExample)
IL (1) IL221540B (enExample)
MA (1) MA34084B1 (enExample)
MX (1) MX2012011340A (enExample)
NZ (1) NZ601729A (enExample)
PE (1) PE20130642A1 (enExample)
PH (1) PH12012501683A1 (enExample)
RU (1) RU2603486C2 (enExample)
SG (2) SG10201505374TA (enExample)
TN (1) TN2012000431A1 (enExample)
TW (2) TW201618806A (enExample)
WO (1) WO2011120924A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2015165964A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165971A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ES2824763T3 (es) * 2014-04-29 2021-05-13 Frank Mattner Tratamiento y a la prevención de la enfermedad de Alzheimer (AD)
EP3137094B1 (en) 2014-04-29 2022-12-07 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
AU2020348947B2 (en) 2019-09-16 2025-11-27 Amgen Inc. Method for external sterilization of drug delivery device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
CA2295740A1 (en) * 1997-07-08 1999-01-21 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
EP1409013B1 (en) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
MXPA05000819A (es) * 2002-07-19 2005-08-29 Cytos Biotechnology Ag Composiciones de vacunas que contienen arreglos de antigeno amiloide beta 1-6.
CN100409896C (zh) * 2003-03-31 2008-08-13 姚志彬 一种老年性痴呆疫苗及其制备方法
WO2006032674A1 (en) * 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CN101318015A (zh) * 2008-06-25 2008-12-10 中山大学 老年性痴呆重组蛋白疫苗及其制备方法

Also Published As

Publication number Publication date
GT201200265A (es) 2014-03-14
NZ601729A (en) 2013-10-25
EP2552489A1 (en) 2013-02-06
CA2793580A1 (en) 2011-10-06
AU2011234656A1 (en) 2012-10-11
CL2012002685A1 (es) 2013-01-25
US20140348871A1 (en) 2014-11-27
RU2603486C2 (ru) 2016-11-27
TW201618806A (zh) 2016-06-01
JP2017008035A (ja) 2017-01-12
AU2011234656B2 (en) 2013-08-01
SG10201505374TA (en) 2015-08-28
BR112012024708A2 (pt) 2016-06-07
MX2012011340A (es) 2012-11-16
TN2012000431A1 (en) 2014-01-30
PH12012501683A1 (en) 2012-11-05
IL221540B (en) 2018-11-29
KR20130018407A (ko) 2013-02-21
WO2011120924A1 (en) 2011-10-06
JP6088422B2 (ja) 2017-03-01
RU2012145734A (ru) 2014-05-10
SG183806A1 (en) 2012-10-30
US20150297692A1 (en) 2015-10-22
AR080810A1 (es) 2012-05-09
CN104436212A (zh) 2015-03-25
US20160101167A1 (en) 2016-04-14
US20130011431A1 (en) 2013-01-10
MA34084B1 (fr) 2013-03-05
CO6630127A2 (es) 2013-03-01
PE20130642A1 (es) 2013-06-19
TW201138805A (en) 2011-11-16
CN102834118A (zh) 2012-12-19
JP2013523682A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
ECSP12012180A (es) Composición que comprende el péptido amiloide beta 1-6 acoplado a una partícula similar a virus y un auxiliar
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
GT201500021A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX377804B (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
MX2013011985A (es) Nanosuspensiones de farmacos secadas por congelamiento.
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
ECSP10010287A (es) Vectores de virus oncolíticos de viruela
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
UY33897A (es) Inhibidores del virus de la hepatitis c
CL2011002643A1 (es) Composicion farmaceutica que comprende r7227, ritonavir y un excipiente farmaceuticamente aceptable; kit para el tratamiento del virus de la hepatitis c.
UA108858C2 (xx) Похідні ізоксалідину
CU20180035A7 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
HN2011000864A (es) Particulas inhalables que comprenden tiotropio
PH12013502177A1 (en) Hepatitis c virus inhibitors
CL2019002133A1 (es) Partícula similar a virus (vlp).
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
TN2013000313A1 (en) Isoxazolidine derivatives
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
PH12015500534B1 (en) Isoxazolidine derivatives
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
UA113048C2 (xx) Противірусні сполуки
CR20140273A (es) Composiciones y métodos para tratar el virus de la hepatitis c